|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Kidney Cancer (clear cell carcinoma)
Kidney cancer forms in the tissues of the kidneys. Metastatic kidney cancer is cancer that has spread from the kidney to other organs in the body. More specifically, clear cell carcinoma is rare type of tumor, usually of the female genital tract, in which the inside of the cells look clear when viewed under a microscope. It is also referred to as clear cell adenocarcinoma and mesonephroma.
[Source: www.cancer.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Kidney Cancer (Clear Cell Carcinoma) Study - L2201
The purpose of this randomized, open-label, multi-center phase II study is to compare the effects of combining a Novartis investigational drug with an existing therapy, when treating people with metastatic clear cell carcinoma of the kidney (Kidney Cancer). An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 2 Participation Duration: Participants will be required to visit their study site every two weeks for approximately two years. One group will be required to inject themselves three times a week and return to the study site every two weeks for an additional infusion treatment. Another group, will be required to take two tablets every day and return to the site every two weeks for an additional infusion treatment. Protocol Number: CRAD001L2201 |